GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Caladrius Biosciences Inc. (CLBS) [hlAlert]

Rating:
Buy NBS
down 90.30 %

NEOSTEM INC. (NBS) rated Buy with price target $3.50 by Morgan Joseph

Posted on: Friday,  Dec 3, 2010  10:25 AM ET by Morgan Joseph

Morgan Joseph rated Buy Caladrius Biosciences Inc. (NASDAQ: CLBS) on 12/03/2010, when the stock price was $13.20. Since
then, Caladrius Biosciences Inc. has lost 90.30% as of 01/08/2016's recent price of $1.28.
If you would have followed this Morgan Joseph's recommendation on CLBS, you would have lost 90.3% of your investment in 1862 days.

NeoStem, Inc. (NeoStem) is engaged in a platform business of operating a commercial autologous (donor and recipient are the same) adult stem cell bank and in pre-disease collection, processing and long-term storage of stem cells from adult donors that they can access for their own future medical treatment. The Company manages a network of adult stem cell collection centers throughout the United States. It also entered the research and development arenas, through the acquisition of a worldwide license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSEL (very small embryonic-like) stem cells. VSELs have many physical characteristics typically found in embryonic stem cells, including the ability to differentiate into specialized cells found in substantially all the different types of cells and tissue that make up the body. In October 2009, NeoStem, Inc. completed the acquisition of China Biopharmaceuticals Holdings, Inc.

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/3/2010 10:25 AM Buy
None
13.20 35.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy